C. Boshoff serves as the Chief Scientific Officer and President of Research & Development at Pfizer Inc., a leading global pharmaceutical company. In his current role, Boshoff is responsible for overseeing the company's scientific research and development efforts, driving innovation, and ensuring the successful development and delivery of new medicines and therapies to patients worldwide. His leadership has been instrumental in advancing Pfizer's pipeline and strengthening its position as a frontrunner in the pharmaceutical industry. Prior to joining Pfizer, Boshoff held several prestigious positions in the field of oncology and medical research. He earned his medical degree from the University of Cape Town and completed his PhD in molecular virology at University College London. Boshoff's early career focused on groundbreaking research in the field of cancer biology, particularly in the areas of viral oncology and the molecular mechanisms of tumorigenesis. His work has been widely published in renowned scientific journals and has contributed significantly to the understanding of cancer development and potential therapeutic targets. Throughout his career, Boshoff has received numerous accolades for his contributions to medical science. He has been recognized for his leadership in oncology research and his dedication to translating scientific discoveries into tangible benefits for patients. At Pfizer, Boshoff continues to champion a patient-centric approach to drug development, fostering collaborations across the industry and academia to accelerate the delivery of innovative treatments. Under his guidance, Pfizer's R&D efforts have expanded to address a wide range of therapeutic areas, from oncology and immunology to rare diseases and infectious diseases, solidifying the company's commitment to improving global health outcomes.